Global medical technology company Fenwal, Inc. is a focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components. Medical professionals and patients in over 60 countries rely on Fenwal technologies for life-saving blood therapies.

From the 10th to the 14th April 2011, a delegation of French businesses - Agid, Atlantic RF, Biolog-id, Baracoda, Dassault systems, Firefliies RTLS, ID3S, IER, Maintag, Renault, SITL/RFID, Stid and Twiister - lead by the RFID National Centre and supported by Ubifrance and the Aix Country Community, has participated in the 9th edition of RFID Live Journal, the biggest world salon specialised in the RFID technologies in Orlando (Florida, United-States)

The European Commission and the industrials have just defined a certain number of "good practices" for using the identification chips with RFID radiofrequency. Objectif: to protect the consumers

We are delighted to announce that the French company Biolog-id, member of FILRFID, has received the nomination for the "Awards 2011", for the relevance of its RFID application in the traceability of transfusional products. The price will be awarded in the settings of RFID Live, which will take place in Orlando in the United States, from 12th to 14th April of next year: RFID Awards

Two pilot schemes led by the EFS (from 2007 to 2009) and a third one led in collaboration with the Fractionation and Biotechnology Laboratory (LFB / 2009-2010), have allowed the RFID technology to be seized by these two establishments as a possible major application, in the treatment process follow up of different blood products.

Following RFID pilots led by the organization that manages France's blood-donor centers, the French Agency for the Safety of Health Products is considering the creation of a protocol for the use of radio frequency identification on blood products in that country.

The company Biolog/Réseaumatique has developed a very innovative process of traceability for the transfusional security and the management of blood products. An application protected by 20 international patents and elected by the LFB.